Free Trial Information
BioCentury | Jun 30, 2020
Finance

Qiming-backed Gan & Lee hits ceiling to reach $5.2B market cap in first day on Shanghai

The latest in a string of Qiming portfolio companies to go public, Gan & Lee saw its stock gain the maximum allowed by the Shanghai exchange in its first day of trading to bring its...
Read More
BioCentury | Oct 11, 2019
Preclinical News

Oct. 10 Preclinical Quick Takes: Merck-Prokaryotics Inc.-Princeton ID new antibiotic class; plus NIH, Owkin, Genentech and ICR

...Merck, Prokaryotics, Princeton ID new class of antibiotic Merck & Co. Inc. (NYSE:MRK), Prokaryotics Inc. and Princeton...
...Evolution Offers a Way to Foil Drug Resistance" ). BioCentury Staff NIH National Institutes of Health Merck & Co. Inc. Prokaryotics Inc. Princeton...
Read More
BioCentury | Oct 7, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression...
Read More
BioCentury | Sep 25, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression...
Read More
BioCentury | Aug 8, 2019
Translation in Brief

A cool menthol switch for gene expression

ETH Zurich researchers have created a synthetic gene circuit activated by topical menthol to switch on gene expression and protein production in engineered cells. In a July Nature Medicine paper , the team used the circuit...
Read More
BioCentury | Jun 6, 2019
Translation in Brief

CRISPR pioneer Zhang describes new technique to insert genes

Feng Zhang's latest study brings the gene editing field one step closer to correcting and replacing, rather than just disrupting, target genes. The challenge now will be translating the technique from prokaryotic cells to eukaryotic...
Read More
BioCentury | May 31, 2019
Company News

Bio Palette deal expands Beam's base editing toolbox, Japan strategy

Genome editing companies Beam and Bio Palette announced a cross-licensing deal Friday that grants each biotech access to the other's base editing technologies. The deal also signals Beam is looking for additional opportunities in Japan,...
Read More
BioCentury | May 21, 2019
Company News

May 21 Company Quick Takes: Verily in deal with pharmas; plus Amryt-Aegerion, Prokaryotics

...the latter drug. Prokaryotics gets rights to Fundación Medina's antibiotics Fundación Medina (Granada, Spain) granted Prokaryotics Inc....
...not disclosed. Chris Lieu, Staff Writer Alphabet Inc. Amryt Pharma plc Fundacion Medina Novartis AG Novelion Therapeutics Inc. Otsuka Holdings Co. Ltd. Pfizer Inc. Prokaryotics Inc. Sanofi...
Read More
BioCentury | Mar 15, 2019
Finance

SNIPR targets the microbiome

SNIPR's strong IP position in prokaryotic CRISPR drew investors to a $50 million venture round led by Lundbeckfonden Emerge and LSP, the biggest series A yet for a CRISPR antibiotics and autoimmune company. Lundbeckfonden Emerge's...
Read More
BioCentury | Jul 18, 2018
Emerging Company Profile

Ministring theory in practice

Mediphage Bioceuticals Inc.’s ministrings have safety, manufacturing and other advantages that could give conventional plasmids and related vectors a run for their money in the gene therapy space. The newco’s ministrings are linear DNAs with...
Read More
Items per page:
1 - 10 of 43
BioCentury | Jun 30, 2020
Finance

Qiming-backed Gan & Lee hits ceiling to reach $5.2B market cap in first day on Shanghai

The latest in a string of Qiming portfolio companies to go public, Gan & Lee saw its stock gain the maximum allowed by the Shanghai exchange in its first day of trading to bring its...
Read More
BioCentury | Oct 11, 2019
Preclinical News

Oct. 10 Preclinical Quick Takes: Merck-Prokaryotics Inc.-Princeton ID new antibiotic class; plus NIH, Owkin, Genentech and ICR

...Merck, Prokaryotics, Princeton ID new class of antibiotic Merck & Co. Inc. (NYSE:MRK), Prokaryotics Inc. and Princeton...
...Evolution Offers a Way to Foil Drug Resistance" ). BioCentury Staff NIH National Institutes of Health Merck & Co. Inc. Prokaryotics Inc. Princeton...
Read More
BioCentury | Oct 7, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression...
Read More
BioCentury | Sep 25, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression...
Read More
BioCentury | Aug 8, 2019
Translation in Brief

A cool menthol switch for gene expression

ETH Zurich researchers have created a synthetic gene circuit activated by topical menthol to switch on gene expression and protein production in engineered cells. In a July Nature Medicine paper , the team used the circuit...
Read More
BioCentury | Jun 6, 2019
Translation in Brief

CRISPR pioneer Zhang describes new technique to insert genes

Feng Zhang's latest study brings the gene editing field one step closer to correcting and replacing, rather than just disrupting, target genes. The challenge now will be translating the technique from prokaryotic cells to eukaryotic...
Read More
BioCentury | May 31, 2019
Company News

Bio Palette deal expands Beam's base editing toolbox, Japan strategy

Genome editing companies Beam and Bio Palette announced a cross-licensing deal Friday that grants each biotech access to the other's base editing technologies. The deal also signals Beam is looking for additional opportunities in Japan,...
Read More
BioCentury | May 21, 2019
Company News

May 21 Company Quick Takes: Verily in deal with pharmas; plus Amryt-Aegerion, Prokaryotics

...the latter drug. Prokaryotics gets rights to Fundación Medina's antibiotics Fundación Medina (Granada, Spain) granted Prokaryotics Inc....
...not disclosed. Chris Lieu, Staff Writer Alphabet Inc. Amryt Pharma plc Fundacion Medina Novartis AG Novelion Therapeutics Inc. Otsuka Holdings Co. Ltd. Pfizer Inc. Prokaryotics Inc. Sanofi...
Read More
BioCentury | Mar 15, 2019
Finance

SNIPR targets the microbiome

SNIPR's strong IP position in prokaryotic CRISPR drew investors to a $50 million venture round led by Lundbeckfonden Emerge and LSP, the biggest series A yet for a CRISPR antibiotics and autoimmune company. Lundbeckfonden Emerge's...
Read More
BioCentury | Jul 18, 2018
Emerging Company Profile

Ministring theory in practice

Mediphage Bioceuticals Inc.’s ministrings have safety, manufacturing and other advantages that could give conventional plasmids and related vectors a run for their money in the gene therapy space. The newco’s ministrings are linear DNAs with...
Read More
Items per page:
1 - 10 of 43